Summary

Other Scenarios:

Buyer: MGi Pharma, Inc. (MOGN) Last Price: 40.99 Market Cap.: 3.30B
Target: Pharmion Corporation (PHRM) Last Price: 66.23 Market Cap.: 2.47B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
Healthcare 927
Biopharmaceuticals 379
Cardiovascular System 20
Digestive System   3
Hematology 4
Immunology   8
Neurology   34
Obstetrics/Gynecology   4
Oncology 85
Pain Management   10
Surgery   3

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 14)
  • Salagen (Pilocarpine Hydrochloride)
  • Dacogen (Decitabine)
  • Gliadel Wafer (Polifeprosan 20 With Carmustine Implant)
  • Irofulven (Hydroxymethylacylfulvene)
Target (Total: 5)
  • Oral Azacitidine
  • Vidaza (Azacitidine)
  • MGCD0103 (Histone Deacetylase (HDAC) Inhibitor)
  • Amrubicin (Anthracycline)
Buyer
  • Poly ADP-Ribose Polymerase (PARP) Inhibitors
  • Aloxi (Palonosetron)
  • Oral Aloxi (Palonosetron)
  • Saforis (L-Glutamine)
Target
  • Innohep (Tinzaparin Sodium)
  • MGCD0103 (Histone Deacetylase (HDAC) Inhibitor)
  • Oral Azacitidine
  • Vidaza (Azacitidine)

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 10)
  • SuperGen, Inc. (SUPG)
  • Pfizer Inc. (PFE)
  • Merck & Co., Inc. (MRK)
  • Baxter International Inc. (BAX)
Target (Total: 6)
  • GPC Biotech AG (ADR) (GPCB)
  • Celgene Corporation (CELG)
  • salesforce.com, inc. (CRM)
  • MethylGene Inc. (MYG:CA)
Buyer (Total: 4)
  • Bristol Myers Squibb Co. (BMY)
  • AmerisourceBergen Corp. (ABC)
  • McKesson Corporation (MCK)
  • US Oncology, Inc.
Target (Total: 4)
  • US Oncology, Inc.
  • Cardinal Health, Inc. (CAH)
  • McKesson Corporation (MCK)
  • Government - United Kingdom

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 540 417
Revenue Per Employee 835,726.7 647,481.4
Total Revenue 112.5 67.3
Total Expenses 101.3 90.4
Other Revenue 0.0 0.0
Cost of Revenue 38.2 18.2
SG&A Expense 38.7 32.5
Research & Development 22.8 29.1
Other Operating Expense 0.0 0.0
Operating Income 11.2 -23.0
Unusual Income 1.6 8.0
LT Debt to Capital 64.1 0
Fwd P/E 117.14 -56.00
Fwd P/Rev 8.04 9.28
Book Value 145.7 380.0
Curr Portion of LTD/Cap Lease 1.6 0.0

Individual Company Summary

Focused

Buyer

Focused (): Healthcare > Biopharmaceuticals > Oncology

Target

Focused (): Healthcare > Biopharmaceuticals > Oncology

Business Description

Buyer

MGI PHARMA, INC. (MGI) is a biopharmaceutical company focused in oncology and acute care that acquires, researches, develops and commercializes pharmaceutical products that address the unmet needs of patients. MGI focuses its sales efforts solely within the United States where it has retained product rights to its marketable products and product candidates under development. Its late stage product candidates include two product candidates from its acute care franchise (Aloxi for post operative nausea and vomiting (PONV) and Aquavan, a minimal to moderate sedative agent for patients undergoing brief diagnostic or surgical procedures, obtained in its acquisition of Guilford Pharmaceuticals Inc.), oncology (Dacogen for acute myeloid leukemia (AML)) and supportive care (Saforis Powder for Oral Suspension (Saforis)) products, as well as a biologics candidate, amolimogene bepiplasmid. On July 6, 2006, MGI entered into a license agreement with Cilag GmbH (Cilag), a Johnson & Johnson company.

Target

Pharmion Corporation (Pharmion) is a global pharmaceutical company that acquires, develops and commercializes products for the treatment of hematology and oncology patients. It has established a portfolio of approved products and product candidates focused on the hematology and oncology markets. These include Pharmion?s primary commercial products, Vidaza (azacitidine for injection), which it markets and sells as an approved treatment for myelodysplastic syndromes in the United States, Switzerland, Israel and the Philippines. and Thalidomide Pharmion 50 milligram, a therapy for the treatment of multiple myeloma and certain other forms of cancer, which it sells on a compassionate use or named patient basis in certain countries of Europe. Thalidomide Pharmion is approved in Australia, New Zealand, Turkey, Israel, South Korea and Thailand for the treatment of multiple myeloma after the failure of standard therapies. In November 2006, it acquired Cabrellis Pharmaceuticals Corporation.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 67.06 72.65
Operating Margin % -1.18 -40.39
Quick Ratio 3.34 4.49
Current Ratio 3.8 4.89
Coverage Ratio -0.02 -0.08
Total Assets 516.4 451.5
Return on Equity % -4.11 -26.47
Return on Assets % -1.16 -22.28
Cash+ ST Inv. Per Share 1.97 6.96
Total Debt 261.9 0.0
Total Debt to Equity % 179.7 0
Total Debt to Tangible Equity % 1,377.82 0
Debt to Asset % 50.71 0.00

Product Summary

Sector Buyer Target
Healthcare
Biopharmaceuticals
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
Healthcare
Biopharmaceuticals
Cardiovascular System
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Poly ADP-Ribose Polymerase (PARP) Inhibitors
  
Vascular Disorders  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.

Target Products:

  • Innohep (Tinzaparin Sodium)
  
Thromboembolism  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.

Target Products:

  • Innohep (Tinzaparin Sodium)
  
Digestive System  
Gastrointestinal Tract Disorders  
Gastroesophageal Disorders  
Nausea/Vomiting  
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.

Buyer Products:

  • Aloxi (Palonosetron)
  • Oral Aloxi (Palonosetron)
  
Stomatognathic Disorders  
Mucositis  
Immunomodulatory Agents
Therapeutics that treat mucositis by stimulating the immune system.

Buyer Products:

  • Saforis (L-Glutamine)
  
Hematology
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Dacogen (Decitabine)

Target Products:

  • MGCD0103 (Histone Deacetylase (HDAC) Inhibitor)
  • Oral Azacitidine
White Blood Cell (WBC) Disorders
Myelodysplastic Syndromes (MDS)
Antimetabolite Agents
Pyrimidine Analogs
Therapeutics that treat and manage rmyelodysplastic syndrome by interfering with the production of DNA.

Buyer Products:

  • Dacogen (Decitabine)

Target Products:

  • Vidaza (Azacitidine)
Immunology  
Autoimmune Disorders  
Sjogren`s Syndrome  
Palliative Agents  
Cholinergic Agents
Therapeutics that treat the symptoms of a chronic systemic inflammatory disorder characterized by progressive dryness of mucous membranes by stimulating saliva production.

Buyer Products:

  • Salagen (Pilocarpine Hydrochloride)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • AKR-501 (Thrombopoietin Mimetic)
  
Neurology  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • GPC II Inhibitors
  
Obstetrics/Gynecology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Amolimogene Bepiplasmid (DNA Based Immunostimulant - Formerly ZYC101a)
  
Oncology
Head/Neck Cancer  
Palliative Agents  
Cholinergic Agents
Therapeutics that treat dry mouth resulting from radiotherapy for cancer of the head and neck.

Buyer Products:

  • Salagen (Pilocarpine Hydrochloride)
  
Hematology  
Leukemia (White Blood Cell Cancer)  
Myeloid  
Acute  
Myelogenous (AML)  
Antimetabolite Agents  
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage rapidly progressing cancers of the myelogenous cells by inhibiting the production of DNA.

Buyer Products:

  • Dacogen (Decitabine)
  
Neurology  
Brain Cancer  
Glioma  
Glioblastoma  
Alkylating Agents  
Nitrosoureas
Therapeutics that can cross the blood-brain barrier to treat and manage tumors of the glial cells by interacting with DNA and inhibiting cell division.

Buyer Products:

  • Gliadel Wafer (Polifeprosan 20 With Carmustine Implant)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • Dacogen (Decitabine)
  • Irofulven (Hydroxymethylacylfulvene)
  • ZYC300 (DNA Based Immunostimulant)

Target Products:

  • Oral Azacitidine
  • Vidaza (Azacitidine)
  • MGCD0103 (Histone Deacetylase (HDAC) Inhibitor)
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Buyer Products:

  • Poly ADP-Ribose Polymerase (PARP) Inhibitors
  
Respiratory System/Thoracic  
Lung Cancer  
Small Cell Lung Cancer (SCLC)  
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the small cells in the lung by inhibiting a specific enzyme, topoisomerase II, needed for transcription and replication of DNA.

Target Products:

  • Amrubicin (Anthracycline)
  
Urology  
Ovarian Cancer  
Palliative Agents  
DNA Synthesis Inhibitors
Therapeutics that treat and manage ovarian cancer by inhibiting the synthesis of DNA but are not curative.

Buyer Products:

  • Hexalen (Altretamine)
  
Pain Management  
Anesthesia  
General (Systemic)  
Primary  
Hypnotic Agents (Sedatives)
Therapeutics that result in anesthesia by inducing sleep. These therapeutics have no analgesic action.

Buyer Products:

  • AQUAVAN Injection (Propofol)
  
Surgery  
Musculoskeletal System  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.

Target Products:

  • Innohep (Tinzaparin Sodium)
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  GlaxoSmithKline plc (ADR) n/a 129,213.735 12.21 12.17 2.87 2.89 12.60
Celgene Corporation n/a 19,860.224 114.12 52.62 15.69 14.58 8.48
Vion Pharmaceuticals, Inc. n/a 38.882 0.00 -0.96 1,914.50 1,849.70 4.71
Buyer
  GlaxoSmithKline plc (ADR) n/a 129,213.735 12.21 12.17 2.87 2.89 12.60
Schering-Plough Corporation n/a 30,807.112 15.76 14.94 2.65 2.70 2.35
Celgene Corporation n/a 19,860.224 114.12 52.62 15.69 14.58 8.48
Pharmion Corporation n/a 2,467.082 0.00 -56.00 9.64 9.28 8.96
Generex Biotechnology Corporation n/a 144.151 0.00 -8.50 1,637.50 n/a 5.58
Peregrine Pharmaceuticals n/a 85.960 0.00 n/a 14.02 n/a 3.13
Spectrum Pharmaceuticals, Inc. n/a 75.554 0.00 -2.14 5.72 9.78 1.28
A.P. Pharma, Inc. n/a 43.108 0.00 -1.51 154.12 n/a 1.16
Vion Pharmaceuticals, Inc. n/a 38.882 0.00 -0.96 1,914.50 1,849.70 4.71
NeoPharm, Inc. n/a 14.813 0.00 n/a n/a n/a 0.77
Access Pharmaceuticals, Inc. n/a 10.189 0.00 n/a 1,676.47 n/a n/a
Target
  Pfizer Inc. n/a 154,421.887 18.62 9.64 3.18 3.31 n/a
GlaxoSmithKline plc (ADR) n/a 129,213.735 12.21 12.17 2.87 2.89 12.60
sanofi-aventis (ADR) n/a 109,679.174 18.58 11.12 2.51 2.86 n/a
Genentech, Inc. n/a 71,389.037 25.77 21.93 6.09 5.57 n/a
Eli Lilly & Co. n/a 57,555.042 25.80 14.54 3.25 3.18 5.48
Celgene Corporation n/a 19,860.224 114.12 52.62 15.69 14.58 8.48
Millennium Pharmaceuticals, Inc. n/a 4,730.028 0.00 122.08 9.72 9.50 7.38
MGi Pharma, Inc. n/a 3,304.322 0.00 117.14 8.95 8.04 173.86
SuperGen, Inc. n/a 201.748 124.75 17.65 11.18 8.94 2.30
Poniard Pharmaceuticals, Inc. n/a 179.181 0.00 -4.90 n/a 5.60 2.07
Vion Pharmaceuticals, Inc. n/a 38.882 0.00 -0.96 1,914.50 1,849.70 4.71

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  SuperGen, Inc. 13.20% 201.748 124.75 17.65 11.18 8.94 2.30
Pfizer Inc. n/a 154,421.887 18.62 9.64 3.18 3.31 n/a
Merck & Co., Inc. n/a 104,018.133 19.33 15.78 4.33 4.44 5.62
Baxter International Inc. n/a 38,678.422 22.66 19.82 3.43 3.31 5.59
Alpharma Inc. n/a 785.670 14.07 19.64 1.13 1.10 1.93
Ferro Corporation n/a 731.922 65.10 18.99 0.34 0.34 4.41
Patheon, Inc. n/a 295.436 0.00 n/a 0.44 n/a 1.60
Merck KGaA n/a n/a n/a n/a n/a n/a n/a
The Regents of the University of California n/a n/a n/a n/a n/a n/a n/a
Helsinn Group n/a n/a n/a n/a n/a n/a n/a
Target
  GPC Biotech AG (ADR) 66.00% 114.028 0.00 n/a 3.65 n/a 1.51
Celgene Corporation n/a 19,860.224 114.12 52.62 15.69 14.58 8.48
salesforce.com, inc. n/a 6,252.214 543.86 403.21 9.25 9.00 16.95
MethylGene Inc. n/a 100.877 0.00 n/a 6.94 n/a 2.02
Ben Venue Laboratories, Inc. n/a n/a n/a n/a n/a n/a n/a
Ash Stevens, Inc. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  McKesson Corporation n/a 17,478.994 17.80 18.69 0.18 0.18 5.56
US Oncology, Inc. n/a n/a n/a n/a n/a n/a n/a
Buyer
  Bristol Myers Squibb Co. 10.00% 45,446.398 21.44 15.99 2.43 2.34 9.69
AmerisourceBergen Corp. 10.00% 7,329.741 16.05 16.00 0.11 0.11 2.54
McKesson Corporation n/a 17,478.994 17.80 18.69 0.18 0.18 5.56
US Oncology, Inc. n/a n/a n/a n/a n/a n/a n/a
Target
  US Oncology, Inc. 19.00% n/a n/a n/a n/a n/a n/a
Cardinal Health, Inc. 11.00% 20,399.391 10.40 14.32 0.23 0.22 16.38
McKesson Corporation 9.00% 17,478.994 17.80 18.69 0.18 0.18 5.56
Government - United Kingdom n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Pfizer Inc. n/a 154,421.887 18.62 9.64 3.18 3.31 n/a
Celgene Corporation n/a 19,860.224 114.12 52.62 15.69 14.58 8.48
MethylGene Inc. n/a 100.877 0.00 n/a 6.94 n/a 2.02
Buyer
  Johnson & Johnson n/a 178,744.902 16.90 14.37 2.93 2.86 n/a
Pfizer Inc. n/a 154,421.887 18.62 9.64 3.18 3.31 n/a
Roche Holding Ltd. (ADR) n/a 152,328.536 19.21 18.12 3.77 3.89 5.64
GlaxoSmithKline plc (ADR) n/a 129,213.735 12.21 12.17 2.87 2.89 12.60
Novartis AG (ADR) n/a 115,310.846 13.94 14.29 3.03 2.95 4.04
sanofi-aventis (ADR) n/a 109,679.174 18.58 11.12 2.51 2.86 n/a
Merck & Co., Inc. n/a 104,018.133 19.33 15.78 4.33 4.44 5.62
Baxter International Inc. n/a 38,678.422 22.66 19.82 3.43 3.31 5.59
Schering-Plough Corporation n/a 30,807.112 15.76 14.94 2.65 2.70 2.35
Target
  Pfizer Inc. n/a 154,421.887 18.62 9.64 3.18 3.31 n/a
Cardinal Health, Inc. n/a 20,399.391 10.40 14.32 0.23 0.22 16.38
Celgene Corporation n/a 19,860.224 114.12 52.62 15.69 14.58 8.48
McKesson Corporation n/a 17,478.994 17.80 18.69 0.18 0.18 5.56
MGi Pharma, Inc. n/a 3,304.322 0.00 117.14 8.95 8.04 173.86
GPC Biotech AG (ADR) n/a 114.028 0.00 n/a 3.65 n/a 1.51
MethylGene Inc. n/a 100.877 0.00 n/a 6.94 n/a 2.02
Dainippon Sumitomo Pharma Co., Ltd. n/a n/a n/a n/a n/a n/a n/a
US Oncology, Inc. n/a n/a n/a n/a n/a n/a n/a
LEO Pharma A/S n/a n/a n/a n/a n/a n/a n/a
Nippon Shinyaku Co., Ltd. n/a n/a n/a n/a n/a n/a n/a
Ben Venue Laboratories, Inc. n/a n/a n/a n/a n/a n/a n/a
Ash Stevens, Inc. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 369.2 255.9 625.1
Other Revenue 0.0 0.0 0.0
Total Revenue 369.2 255.9 625.1
Cost of Revenue 121.6 70.0 191.6
SG&A Expense 163.4 125.2 288.5
Depreciation & Amortization 0.0 9.9 9.9
Research & Development 84.7 91.9 176.6
Interest Expense 0.0 0.0 0.0
Other Operating Expense 0.0 0.0 0.0
Unusual Expense (Income) 3.9 62.3 66.2
Total Expenses 373.6 359.2 732.8
Operating Income -4.4 -103.3 -107.7
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 0.1 8.1 8.2
Other, Net -0.1 0.0 -0.1
Income Before Taxes -4.4 -95.3 -99.7
Income Taxes 1.6 5.3 6.9
Income After Taxes -6.0 -100.6 -106.6
Net Income - Excl. Xord. Items -6.0 -100.6 -106.6
Net Income - Incl. Xord. Items -6.0 -100.6 -106.6
Income Avail. to Common -6.0 -100.6 -106.6
Share Items
Basic Avg. Shares Outstanding 80.2 37.0 117.2
Basic EPS - Excl. Xord. Items n/a n/a -0.91
Basic EPS - Incl. Xord. Items n/a n/a -0.91
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 83.3 37.0 120.3
F.D. EPS - Excl. Xord. Items n/a n/a -0.89
F.D. EPS - Incl. Xord. Items n/a n/a -0.89
Balance Sheet
Assets
Cash and Equivalents 79.0 135.0 214.0
ST Investments 85.3 122.6 207.9
Accounts Receivable 135.1 45.4 180.5
Inventory 36.4 13.0 49.4
Other Current Assets 4.9 14.0 18.8
Current Assets 340.6 330.0 670.6
PPE 20.8 0.0 20.8
Accum D&A -9.4 0.0 -9.4
PPE, Net 11.4 11.0 22.3
Goodwill & Intangibles 126.7 104.7 231.4
Long Term Investments 26.1 0.0 26.1
Other Assets 0.0 0.0 0.0
Other LT Assets 11.6 5.8 17.5
Total Assets 516.4 451.5 967.9
Liabilities
Accounts Payable 13.2 10.1 23.3
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 72.8 57.5 130.2
ST Debt 0.0 0.0 0.0
Curr Port of LTD & Cap Lease Oblg 1.6 0.0 1.6
Other (Current) Liabilities 2.0 0.0 2.0
Current Liab. 89.6 67.5 157.2
LT Debt 260.3 0.0 260.3
Total LT Debt 260.3 0.0 260.3
Deferred Taxes 0.0 3.0 3.0
Other LT Liab. 20.8 1.0 21.8
Total Liabilities 370.7 71.5 442.2
Shareholders Equity
Common Stock 0.8 0.0 0.8
Additional Paid in Capital 609.9 627.5 1,237.4
Retained Earnings -466.9 -263.2 -730.2
Other Equity 2.0 15.7 17.7
Total Equity 145.7 380.0 525.8
Total Liab. & Equity 516.4 451.5 967.9
Shares Outstanding 80.5 37.2 117.7
Cash Flow
Operating Cash Flow
CF Net Income -6.0 -100.6 -106.6
CF Depreciation 11.2 12.4 23.6
CF Deferred Taxes 0.0 0.0 0.0
Other Non-Cash Items 24.4 3.4 27.8
Change in Working Capital -1.1 20.2 19.1
Total Cash From Operating Activities 28.6 -64.7 -36.1
Investing Cash Flow (not calculated)
Capital Expenditures -5.8 -6.7 -12.5
Other Investing Cash Flows -13.3 -32.1 -45.4
Total Cash From Investing Activities -19.1 -38.8 -57.9
Financing Cash Flow (not calculated)
Dividends Paid 0.0 0.0 0.0
Purchase Or Sale of Stock 17.1 6.1 23.2
Purchase and Retirement of Debt -0.3 -0.9 -1.2
Other Financing Cash Flow 2.6 130.8 133.4
Total Cash From Financing Activities 19.5 135.9 155.4
Exchange Rate Effects 0.0 3.8 3.8
Net Change in Cash 28.9 36.2 65.1
Cash Taxes Paid 0.9 11.4 12.2
Cash Interest Paid 5.9 0.4 6.4